By targeting GIP, GLP-1, and glucagon receptors, the investigational triple agonist could mark the next evolution in incretin ...
Amylin-based petrelintide has achieved good results at Phase II for obesity, showing 8-11% weight loss and a good side effect profile.
Just a small amount of recorded speech could identify type 2 diabetes using an AI-based screening tool, research presented at a scientific conference suggests.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results